When R&D is Bad for Patients : Strategic Price Control Under External Reference Pricing in the Presence of a Tactical Firm
Year of publication: |
[2021]
|
---|---|
Authors: | Zhang, Yingxin ; Gupta, Shubham ; Kumar, Subodha ; Hu, Xiangpei |
Publisher: |
[S.l.] : SSRN |
Subject: | Preismanagement | Pricing strategy | Preisregulierung | Price regulation | Arzneimittel | Pharmaceuticals | Theorie | Theory |
Description of contents: | Abstract [papers.ssrn.com] |
Extent: | 1 Online-Ressource |
---|---|
Type of publication: | Book / Working Paper |
Language: | English |
Notes: | Nach Informationen von SSRN wurde die ursprüngliche Fassung des Dokuments October 15, 2021 erstellt Volltext nicht verfügbar |
Source: | ECONIS - Online Catalogue of the ZBW |
-
Generic competition and price regulation in pharmaceuticals : evidence from the European Union
Tuncay, Berna, (2020)
-
Price-cap regulation, uncertainty and the price evolution of new pharmaceuticals
Shajarizadeh, Ali, (2015)
-
An empirical analysis of the multimarket contact theory in pharmaceutical markets
Coronado, Javier, (2014)
- More ...
-
Zhang, Yingxin, (2021)
-
To Help or Not to Help : A Game-Theoretic Analysis of Regulation GPOs' Price-Ceiling Policy
Zhang, Yingxin, (2020)
-
Gupta, Shubham, (2020)
- More ...